Single-nucleotide polymorphism genotyping for disease association studies.

Myriam Fornage; Peter A Doris

doi:10.1385/1-59259-850-1:159

Home/Archive/PubMed

PubMed · 16028683

Single-nucleotide polymorphism genotyping for disease association studies.

Myriam Fornage·Peter A Doris

View original source ↗Export metadata ↓

Abstract

The Human Genome Project has led to the discovery of millions of DNA sequence variants in the human genome. The majority of these variants are single-nucleotide polymorphisms (SNPs). Availability of an ultra-high-density SNP map, combined with improvement in genotyping technologies and efficient analytical approaches, opens the possibility of fulfilling the promise of SNP association studies to reveal why some individuals are more susceptible to common chronic diseases such as hypertension and stroke. With millions of SNPs spread throughout the human genome, it is neither practical nor necessary to genotype every single SNP in population samples for association studies. Linkage disequilibrium between sites suggests that it is possible to detect disease association using a relatively sparse collection of SNPs. While the cost associated with assaying a comprehensive set of SNPs is still significant, several technologies show great promise for high-efficiency SNP genotyping. This chapter focuses on two of them: the 5'-nuclease assay and mass spectrometry genotyping.

Explore related subjects

Base Sequence Genetic Predisposition to Disease Genotype Humans Linkage Disequilibrium Mass Spectrometry Polymerase Chain Reaction Polymorphism, Single Nucleotide Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Myriam Fornage, Peter A Doris. 2005. Single-nucleotide polymorphism genotyping for disease association studies.. https://doi.org/10.1385/1-59259-850-1%3A159

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2016

miR-503-3p promotes epithelial-mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin.

Although progress in clinical and basic research has significantly increased our understanding of breast cancer, little is known about the molecular mechanism underlying breast cancer metastasis. Identification of effective therapeutic targets to prevent breast cancer metastasis is urgently needed. The function of miR-503-3p has been investigated in other cancers, but its role in breast cancer remains undefined. Here, we found that miR-503-3p was overexpressed in breast cancer tissue and plasma compared with adjacent normal breast tissue and with plasma from healthy individuals. Moreover, we identified miR-503-3p to be an oncogene of breast cancer cell proliferation, migration and invasion. Upregulation of miR-503-3p in breast cancer cells inhibited expression of epithelial-mesenchymal transition (EMT)-related protein SMAD2 and the epithelial marker protein E-cadherin by directly binding to their mRNA 3' untranslated region, whereas increased expression of mesenchymal marker proteins, including vimentin and N-cadherin. Taken together, our findings support a critical role for miR-503-3p in induction of breast cancer EMT and suggest that plasma miR-503-3p may be a useful diagnostic biomarker for breast cancer.

Base Sequence↗

PubMed2007

Highly sensitive detection of cytotoxicity using a modified HSP70B' promoter.

We have previously found that the DNA fragment from nucleotides (nts) -287 to +110 in the HSP70B' gene is a functional promoter responding to Cadmium Chloride-induced cytotoxicity (Wada et al., Biotechnol Bioeng, 92, 410-415, 2005). In order to increase the cytotoxic response of this promoter, we first determined the location of the cytotoxic responding element (CRE) and then constructed tandem repeats of the CRE in front of the HSP70B' promoter. 5'- and 3'-deletion analysis revealed that the DNA fragment from nts -192 to -56 in the HSP70B' gene induces a significant response to cytotoxicity. When the AP-1 binding site in this region was mutated, the basal activity of HSP70B' gene promoter decreased but the cytotoxic response was unchanged. Thus, the CRE is located in nts -192 to -56 in the HSP70B' promoter, and the AP-1 binding site is not essential for the cytotoxic response. In addition, cells transfected with a luciferase construct carrying three tandem repeats of the CRE upstream of the HSP70B' promoter and containing AP-1 binding site mutation, showed a 2.28-fold higher response than that of no repeats. Moreover, the detection limit of Cadmium Chloride in the cells was 382 pmol/mL. Thus, highly sensitive sensor cells for Cadmium Chloride can be constructed using a HSP70B' promoter construct containing upstream tandem repeats of the CRE and mutation of the AP-1 binding site.

Base Sequence↗

PubMed2007

Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia.

Synaptotagmin XI (Syt11) is a member of the synaptotagmin family, which is localized in cells either in synaptic vesicles or the cellular membrane, and is known to act as a calcium sensor. The Syt11 gene is located on chromosome locus 1q21-q22, which was previously reported as a major susceptibility locus of familial schizophrenia. Here, we present evidence for an association between the number of 33-bp repeats in the promoter region of the Syt11 gene and schizophrenia. We found that the transcriptional activity of the gene is affected by the number of 33-bp repeats, which include an Sp1 binding site, suggesting that the excessive expression of Syt11 can be associated with schizophrenia. Another (single nucleotide) polymorphism in the Syt11 5'UTR region, where the potent transcription factor YY1 can bind, also affects the transcriptional activity of Syt11.

Base Sequence↗